Clinical Trial Update: Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence [Phase 2]

View source ↗

Summary

Phase 2 study evaluating H56:IC31 for preventing recurrence of pulmonary tuberculosis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• H56:IC31

Snippet

Sponsor: International AIDS Vaccine Initiative | Conditions: Tuberculosis, Pulmonary | Phase 2 | Status: COMPLETED | Results posted: 2026-02-24